List of Ofev drug patents

Ofev is owned by Boehringer Ingelheim.

Ofev contains Nintedanib Esylate.

Ofev has a total of 5 drug patents out of which 0 drug patents have expired.

Ofev was authorised for market use on 15 October, 2014.

Ofev is available in capsule;oral dosage forms.

Ofev can be used as use of nintedanib for slowing the rate of decline in pulmonary function in patients with systemic sclerosis-associated interstitial lung disease (ssc-ild).

The generics of Ofev are possible to be released after 07 June, 2029.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7119093 BOEHRINGER INGELHEIM 3-Z-[1-(4-(N-((4-Methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone-monoethanesulphonate and the use thereof as a pharmaceutical composition
Feb, 2024

(1 year, 20 days from now)

US6762180 BOEHRINGER INGELHEIM Substituted indolines which inhibit receptor tyrosine kinases
Oct, 2025

(2 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10154990 BOEHRINGER INGELHEIM Medicaments for the treatment or prevention of fibrotic diseases
Dec, 2025

(2 years from now)

US10105323 BOEHRINGER INGELHEIM Pharmaceutical dosage form for immediate release of an indolinone derivative
Jun, 2029

(6 years from now)

US9907756 BOEHRINGER INGELHEIM Capsule pharmaceutical dosage form comprising a suspension formulation of an indolinone derivative
Jun, 2029

(6 years from now)

Exclusivity Exclusivity Expiration
New Indication (I) Mar 9, 2023
Orphan Drug Exclusivity (ODE) Sep 6, 2026

Drugs and Companies using NINTEDANIB ESYLATE ingredient

Market Authorisation Date: 15 October, 2014

Treatment: Use of nintedanib for slowing the rate of decline in pulmonary function in patients with systemic sclerosis-associated interstitial lung disease (ssc-ild)

Dosage: CAPSULE;ORAL

How can I launch a generic of OFEV before it's patent expiration?
More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in